Menu

CME Corner

Active Programs

The Pharmacist's Role in Advanced or Metastatic Breast Cancer

Cyclin-dependent kinase (CDK) 4/6 inhibition significantly prolongs progression-free survival (PFS) in patients with metastatic breast cancer (mBRCA) whose disease progresses on endocrine therapies. This activity will examine emerging evidence and best practices supporting the use of CDK4/6 inhibitors. This activity was originally presented as a webcast series on the following 4 dates: February ...

  • Online Presentation Online Presentation
  • ACPE

Evolving Standards of Care in Metastatic Prostate Cancer

For patients with metastatic prostate cancer (mPRCA), the number of metastases has prognostic and therapeutic implications. Clinicians who treat patients with mPRCA need to recognize patients with oligometastatic prostate cancer and be aware that management of patients with fewer than 5 metastases is different from that of patients with polymetastatic disease. Recommendations for the initial manag ...

  • Online Presentation
  • ACCME

Expired Programs

Metastatic Colorectal Cancer: Applying Evidence-based Recommendations for Evaluation and Management

Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS and NRAS) and BRAF mutations, as the presence of such mutations has implications for treatment. Clinical practice is variable, however, and many patients do not receive guideline-based care. This activity will e ...

  • Online Presentation
  • ACCME
  • ANCC
Main Menu
EDITOR'S PICKS